improve its concentration at the tumour site without excessive accumulation in normal tissues. Here we describe our first results.
The monoclonal antibody fragment F(ab')2-IC12 was prepared from immunopurified IC12 by the method of Lamoyi and Nisonoff (1983) as previously described . Radiolabelling with 1251 was carried out by the chloramine T method to a very low specific activity (0.6 pCi ugg 1). This ensured minimal loss of immunological activity, reduced possible deiodination in vivo and enabled large doses to be used without incurring excessively high radioactivity levels which would result in the need to add unlabelled fragment to arrive at the different amounts injected. The xenograft used in this study was derived from a human colonic adenocarcinoma cell line 'MAWI'. After implanting into nude mice the 'MAWI' xenograft expressed moderate amounts of CEA at the cell surface but did not secrete measurable CEA into the mouse circulation. Tumour weights were between 14 and 385 mg.
Tumour-bearing mice were injected in groups of four with doses of the labelled F(ab')2-IC12 over the range 4, 58, 117, 234 and 380,g. Groups of mice were sacrificed and tissues excised for counting at 4, 24 and 48 h after injection. In this preliminary study only blood and tumour were examined. The choice of blood as an index of normal tissue radioactivity was made since the concentration of radiolabelled fragment in this tissue had been shown to be higher than in any other normal tissue except kidney . Moreover, the presence of radioactivity in the blood is likely to be the dose limiting factor which could induce toxicity to the bone marrow and cause myelosuppression. The results were calculated as the absolute concentration (jgg-1) of F(ab')2-IC12.
The results at the 4pg dose level (Figure la) show that by 4 h after injection the tumour accumulates approximately 0. 15 Mg F(ab')2-1C12 g1 which is maintained up to 24 h and then falls to 0.09 jug g-1 by 48 h. Concentrations of fragment in the blood were initially much higher than that in tumour but fell rapidly to about 0.04,ygg-1 at 24h and were almost undetectable by 48 h. These results are in accordance with our previous findings with F(ab')2-IC12 where 4.0% of the injected dose was present g-1 tumour up to 24 h after which time a net loss of fragment occurred . The rapid clearance of the fragment from the circulation was reflected in high tumour to blood ratios at 48 h (Table I ). This phenomenon with fragments has been well established by many laboratories (Wilbanks et al., 1981; Buchegger et al., 1983; Wahl et al., 1983; Harwood et al., 1985) .
The effect of increasing the administered dose of F(ab')2-1C12 on the relative concentrations in tumour and blood are shown in Figures lb-Id. As expected an increase in dose resulted in an increase in the absolute concentration of label in the tumour at each time point but the percentage of the injected dose associated with the tumour declined. Therefore, the higher the dose the more gradual the increase in uptake in the tumour.
It is also noteworthy that at all dose levels studied, circulatory clearance was incomplete at 24 h but essentially complete by 48 h. However, concentrations of label in the tumour, although diminished, were still appreciable at 48 h after injection. Table I summarises the effect of this on the tumour to blood ratios which were dose dependent at 24 h and decreased with increasing dose, but with the exception of the highest dose, were unaffected by dose changes at 48 h. These results stress the potential importance of circulatory clearance mechanisms in tumour therapy and have been discussed in the previous report (Rogers et al., 1986) .
The ratio (r) (see Table I ) has been used to denote the increased uptake of fragment in tumour Results are shown as the percentage of the injected dose, the absolute 'uptake' in jigg-1 and as the ratio (r).
The ratio (r) denotes the increased 'uptake' as a factor over that achieved at the 4 jug dose level and was calculated as absolute 'uptake' for increased dose absolute 'uptake' for the 4 jig dose T: B = tumour to blood ratio. The figures represent mean values for each group of mice. Variation between mice, ommitted for clarity, was within 12%.
with increasing doses as a factor over the uptake achieved at the 4,ug dose. Thus at 24 and 48 h after injection a 100-fold increase in administered fragment resulted in a 15-and 21-fold (Table II) . This shows that the increasing dose levels over the range studied do not significantly lower the relative localisation of F(ab')2-lC12 fragments in the tumour compared to their concentration in blood.
It is worth noting that, since the concentration of fragment in tumour is still significant at the last time point studied but almost cleared from the blood, the effective localisation indicated by our data (see Table II Our experiments show that, despite the adverse effect of dose escalation on the tumour to blood ratios at 4 and 24h, antibody fragments may be useful in tumour immunoradiotherapy. Our data indicate that increased doses of F(ab')2 fragments in man may help compensate for their reduced concentration at the tumour site with minimal effect on the normal tissue distribution.
